乳腺不典型导管增生管理的最新进展
乳腺经皮活检发现的不典型导管增生(ADH)与导管原位癌(DCIS)鉴别最依赖病理医生且低估风险最高,常规行手术切除。一项纳入6458个病灶的Meta分析显示,手术切除者升级率为29%, surveillance管理者为5%,均高于BI-RADS允许随访的2%阈值,异质性I²=80%。
要点
- ADH经手术切除后升级为浸润癌或DCIS的比率为29%, surveillance管理为5%,均超过BI-RADS的2%随访阈值。
- ADH与DCIS的鉴别仅依据大小,是最依赖病理医生且低估风险最高的病变。
- Meta分析异质性I²=80%,提示需系统综述合成证据以制定指南。
核心结论
- 手术切除或 surveillance管理的ADH升级率分别为29%和5%,即使按活检引导方式、技术、针径、病灶是否完全去除分层,各亚组升级率均高于2%。
研究设计与样本
- 针对经皮乳腺活检发现的不典型导管增生(ADH)管理的综述,引用一项纳入6458个病灶的Meta分析。
诊断标准与关键数值
- ADH与DCIS的鉴别仅依据大小,其余特征与DCIS一致;BI-RADS允许随访的阈值为2%;手术切除的ADH升级率为29%, surveillance管理为5%;Meta分析异质性I²=80%。
临床应用与阅片要点
- 作者认为,在选定亚组中可考虑以 surveillance替代手术,依据是BI-RADS的2%随访阈值;但近期Meta分析结果不支持该做法。
局限性
- 支持 surveillance的单中心研究样本量有限,升级率低。
- Meta分析异质性高(I²=80%),需系统综述合成证据以获得可推广、适于指南制定的结果。
- 经皮活检取材有限,本质上妨碍预测ADH相关恶性肿瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Among lesions with uncertain malignant potential found at percutaneous breast biopsy, atypical ductal hyperplasia (ADH) carries both the highest risk of underestimation and the closest and most pathologist-dependent differential diagnosis with ductal carcinoma in situ (DCIS), matching the latter's features save for size only. ADH is therefore routinely surgically excised, but single-centre studies with limited sample size found low rates of upgrade to invasive cancer or DCIS. This suggests the possibility of surveillance over surgery in selected subgroups, considering the 2% threshold allowing for follow-up according to the Breast Imaging Reporting and Data System. A recent meta-analysis on 6458 lesions counters this approach, confirming that, surgically excised or managed with surveillance, ADH carries a 29% and 5% upgrade rate, respectively, invariably higher than 2% even in subgroups considering biopsy guidance and technique, needle calibre, apparent complete lesion removal. The high heterogeneity (I2 = 80%) found in this meta-analysis reaffirmed the need to synthesise evidence from systematic reviews to achieve generalisable results, fit for guidelines development. Limited tissue sampling at percutaneous biopsy intrinsically hampers the prediction of ADH-associated malignancy. This prediction could be improved by using contrast-enhanced breast imaging and applying artificial intelligence on both pathology and imaging results, allowing for overtreatment reduction.
引用
- Schiaffino S, Cozzi A, Sardanelli F, et al. An update on the management of breast atypical ductal hyperplasia. Br J Radiol. 2020. PMID: 32207989. doi:10.1259/bjr.20200117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。